Abstract:92 Background: Systemic administration of checkpoint inhibitors alone and especially concurrent with intratumoral administration of oncolytic herpes simplex viruses (oHSV) have a major impact on cancer therapy marred by rare failures of healthy organs. Methods: We constructed 3 recombinant oHSVs expressing no immunomodulatory genes (T1 series), murine or human IL-12 (T2 series) and murine or human IL-12 and anti-PD-1 antibody (T3 series). We compared 1) the oncolytic effects of a single or multiple intratumoral injection(s) of T1, T2 and T3 series oHSVs, 2) the effectiveness of intratumoral injection of T3 oHSV with systemic administration of anti PD-1 ab and IL12 alone or in combinations with T1. Results: Insertion of gene encoding PD-1 Ab significantly augmented the oncolytic activity of oHSV bereft of immunostimulatory genes (T1 series) or expressing IL-12 alone (T2 series). In syngeneic mice the T3 series oHSV expressing murine IL-12 and PD-1 Ab was effective against a variety of murine tumors. Concurrent with enhanced cytolytic activity the T3 induced significant intratumoral accumulation of IL-12, PD-1 Ab and IFN-γ. Consistent with an earlier report of an inverse correlation between the volume of the tumor and the quantity of retained IFN-γ. The most effective oncolytic effect resulted from the administration of T3855 expressing both IL12 and anti PD-1 antibody or T2850 concurrently with intraperitoneal administration of anti PD-1 antibody alone. The least effective were single intraperitoneal administration of IL12 or PD-1 antibody. Intratumoral injection of T3 oHSV was most effective against murine tumors in comparison of either systemic administration of anti PD-1 ab and IL12 or intratumoral injection of T1 in combinations of systemic administration of anti PD-1 ab and IL12. Conclusions: We report the marriage in a single therapeutic agent of three distinct cancer therapies: the targeting of cancer cells by oncolytic viruses, the stimulation of immune system by IL12, and the production of immunotherapeutic antibodies against PD-1. The significant finding reported in this article is that the anti-tumor responses remain concentrated in the tumor environment.

Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy

Efficacy and Safety of Oncolytic Virus Immunotherapy in Advanced Malignancies: A Systematic Review of 161 Clinical Studies

Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy

New Generation of Oncolytic Herpesviruses Embodying Immunotherapeutic Genes Encoding IL-12 and Anti-Pd-1 Antibody.

The Promise of Immune Stimulatory Oncolytic Viruses

Targeting Cancers with oHSV-Based Oncolytic Viral Immunotherapy

Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?

An Armed Oncolytic Virus Enhances the Efficacy of Tumor-Infiltrating Lymphocyte Therapy by Converting Tumors to Artificial Antigen-Presenting Cells in Situ.

A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy

Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens.

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials

Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response

Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1

Viral vectors expressing interleukin 2 for cancer immunotherapy.

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer

Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy

Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy

Simultaneous Expression of Different Therapeutic Genes by Infection with Multiple Oncolytic HSV-1 Vectors

Oncolytic virotherapy: basic principles, recent advances and future directions

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

Oncolytic Viruses in Cancer Immunotherapy